Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 31;17:1007–1024. doi: 10.2147/DDDT.S399290

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Wu et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Network pharmacology predicted the possible herb-compound-target-pathway interaction in baicalin mediating the anti-IBD effect. (A) The structural information (B) Venn analysis of disease targets (C) Venn analysis of the targets for the treatment of IBD with baicalin. (D) PPI network. The size and color of the nodes are set according to the betweenness centrality, and the larger the node, the darker the color, indicating that the target is the core gene. (E)The top 10 targets of baicalin against IBD.(F) GO enrichment analysis (G) The KEGG enrichment analysis of the detailed pathways.